Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. Clinuvel Pharmaceuticals Limited
  6. Summary
    CUV   AU000000CUV3

CLINUVEL PHARMACEUTICALS LIMITED

(CUV)
  Report
End-of-day quote. End-of-day quote Australian Stock Exchange - 09/24
43.26 AUD   -0.73%
09/22CLINUVEL PHARMACEUTICALS : Key Events and Announcements
PU
09/21CLINUVEL PHARMACEUTICALS : Confirms AGM Date
PU
09/13CLINUVEL PHARMACEUTICALS : Presentation H.C. Wainwright Global Investment Conference
PU
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Australian Stock Exchange
09/20/2021 09/21/2021 09/22/2021 09/23/2021 09/24/2021 Date
40.75 40.25 41.94 43.58 43.26 Last
133896 213681 274607 214246 205640 Volume
-2.30% -1.23% +4.20% +3.91% -0.73% Change
Estimated financial data (e)
Sales 2022 64,6 M 46,9 M 46,9 M
Net income 2022 30,9 M 22,4 M 22,4 M
Net cash position 2022 108 M 78,3 M 78,3 M
P/E ratio 2022 71,0x
Yield 2022 0,10%
Sales 2023 92,3 M 67,0 M 67,0 M
Net income 2023 42,3 M 30,7 M 30,7 M
Net cash position 2023 135 M 98,3 M 98,3 M
P/E ratio 2023 51,5x
Yield 2023 0,13%
Capitalization 2 137 M 1 549 M 1 551 M
EV / Sales 2022 31,4x
EV / Sales 2023 21,7x
Nbr of Employees -
Free-Float 79,2%
More Financials
Company
Clinuvel Pharmaceuticals Limited is a biopharmaceutical company. The Company is focused on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders, as well as healthcare solutions for the general population. The CompanyÔÇÖs principal activity consists of commercializing and distribution in Europe and the United States of its drug candidate SCENESSE for the... 
More about the company
Ratings of Clinuvel Pharmaceuticals Limited
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C-
More Ratings
All news about CLINUVEL PHARMACEUTICALS LIMITED
09/22CLINUVEL PHARMACEUTICALS : Key Events and Announcements
PU
09/21CLINUVEL PHARMACEUTICALS : Confirms AGM Date
PU
09/13CLINUVEL PHARMACEUTICALS : Presentation H.C. Wainwright Global Investment Conference
PU
09/02CLINUVEL PHARMACEUTICALS LIMITED : Ex-dividend day for final dividend
FA
08/26CLINUVEL PHARMACEUTICALS : Investor Webinar Financial Results
PU
08/26CLINUVEL PHARMACEUTICALS' : Net Profit Jumps 64% on Higher Drug Demand
MT
08/25CLINUVEL PHARMACEUTICALS : Newsletter 4 - August 2021
PU
08/25CLINUVEL PHARMACEUTICALS : Corporate Presentation - FY2021 Results
PU
08/25CLINUVEL PHARMACEUTICALS : Delivers Record Revenues and Profit
PU
08/25Clinuvel Pharmaceuticals Limited Declares Annual Unfranked Dividend for the Year Ending..
CI
08/25CLINUVEL PHARMACEUTICALS : Appendix 4E and Preliminary Financial Report
PU
08/25Clinuvel Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended June ..
CI
08/10CLINUVEL PHARMACEUTICALS' : Neuroprotective Drug Achieves High Tolerance in Stroke Patient..
MT
08/09CLINUVEL PHARMACEUTICALS : Afamelanotide well tolerated by first stroke patients
PU
08/09CLINUVEL Afamelanotide Tolerates by First Stroke Patients
CI
More news
News in other languages on CLINUVEL PHARMACEUTICALS LIMITED
08/27MÄRKTE ASIEN/Zurückhaltung vor Jackson Hole - PBoC stützt Schanghai
08/26Le bénéfice net de Clinuvel Pharmaceuticals bondit de 64 % en raison de la hausse de la..
2019ORIGINAL-RESEARCH : Clinuvel Pharmaceuticals Ltd (von Sphene Capital GmbH): Buy
2019HEIßE AKTIENTIPPS : Lust oder Frust?
2019ORIGINAL-RESEARCH : Clinuvel Pharmaceuticals Ltd (von Sphene Capital GmbH): Buy
More news
Chart CLINUVEL PHARMACEUTICALS LIMITED
Duration : Period :
Clinuvel Pharmaceuticals Limited Technical Analysis Chart | CUV | AU000000CUV3 | MarketScreener
Technical analysis trends CLINUVEL PHARMACEUTICALS LIMITED
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 43,26 AUD
Average target price 33,92 AUD
Spread / Average Target -21,6%
EPS Revisions
Managers and Directors
Philippe Jacques Wolgen Chief Executive Officer, MD & Director
Darren M. Keamy Chief Financial Officer & Secretary
Willem A. Blijdorp Chairman
Dennis J. Wright Chief Scientific Officer
Lachlan Hay Global Director-Operations
Sector and Competitors
1st jan.Capi. (M$)
CLINUVEL PHARMACEUTICALS LIMITED93.82%1 549
CSL LIMITED10.18%103 032
WUXI BIOLOGICS (CAYMAN) INC.14.59%64 160
SAMSUNG BIOLOGICS CO.,LTD.11.62%51 643
BIOGEN INC.19.13%43 475
ALEXION PHARMACEUTICALS, INC.0.00%40 336